AGEN - Agenus Inc

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.

52W High

$7.34

52W Low

$1.38

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.44

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

3.52

EV/EBITDA (<8 favorable)

-2.43

EV/Revenue (<3 favorable)

2.15

P/S (TTM) (<3 favorable)

1.36

P/B (<3 favorable)

218.61

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

1.69%

Institutions (25–75% balanced)

30.11%

Shares Outstanding

31,864,100

Float

31,323,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

101,706,000

Gross Profit (TTM)

-50,034,000

EPS (TTM)

-7.06

Profit Margin (>10% good)

-1.63%

Operating Margin (TTM) (higher better)

-0.65%

ROE (TTM) (>15% strong)

-12.79%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.09

Momentum

Bearish momentum

Value

-0.0994

-0.0963

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025